Mercury Bio

About Mercury Bio

Mercury Bio is a biotechnology company focused on developing a novel platform using engineered exosomes (yEV™) for targeted intracellular delivery of proteins, nucleic acids, and small-molecule drugs. Their mission is to enable cell-specific delivery of therapeutic cargo, overcoming limitations of off-target effects and advancing novel treatments through biocompatibility and scalability.

Products & Services

yEV™ Platform:A drug delivery technology using yeast-derived extracellular vesicles engineered for targeted delivery of molecular cargo to specific cells, with advantages like all-organ access, high-cargo capacity, shelf stability, and the ability to cross the blood-brain barrier.

Neurological Pipeline:Therapies targeting the central nervous system, including treatments for malignant brain tumors and neurological inflammation, using yEV™ to deliver proteins across the blood-brain barrier.

Structural Pipeline:Regenerative therapies for bone and collagen in collaboration with Frame Bio, focusing on delivering proteins to wound sites for skeletal and connective tissue disorders.

Metabolic Pipeline:Development of a GLP-1 therapy for obesity and type 2 diabetes management, delivered via yEV™ technology to enhance insulin production and control blood sugar levels.

Viral Pipeline:Preclinical study of a COVID therapeutic using yEV™ as a stable, targeted delivery alternative to lipid nanoparticle systems.

Specialties

Extracellular Vesicle Drug Delivery Targeted Intracellular Delivery Machine Learning for Targeting Ligands Neurotherapeutics Regenerative Therapies Metabolic Therapies Viral Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 2000000 MR: - FA: $2M FAN: 2000000	D: 2023-08-30 FD: 2023-08-30	-

Seed Latest

2023-08-30

$2.0M

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Richard Sayre

Chief Scientific Officer

T

Tanya Vinogradova-Shah

Director of Research

C

Callum Bell, Ph.D.

Bioinformatics Director

M

Mikhail Sinev

FERMENTATION DIRECTOR

A

Alex Pertzev

Senior Research Scientist

C

Christopher Johnston

Senior Research Scientist

View 16 more team members with Pro

Unlock Full Team Directory

Recent News

Mercury Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised